Search clinical trials for: Hepatocellular Carcinoma Recurrence

Total 33481 results

Qilu Hospital of Shandong University

Recruiting

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Carcinoma, Hepatocellular

China
Zhujiang Hospital

Not yet recruiting

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Recurrence | Surgery | Hepatocellular Carcinoma Resectable

China
Chen Xiaoping

Not yet recruiting

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

HCC
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors

Recurrent or Metastatic Solid Tumors

United States
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Zhujiang Hospital

Not yet recruiting

Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS

Recurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor Cell

China
Chen Xiaoping

Not yet recruiting

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

HCC
Mayo Clinic

Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Malignant Solid Neoplasm | Renal Cell Carcinoma | Hepatocellular Carcinoma | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
Zhujiang Hospital

Not yet recruiting

Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy

Hepatocellular Carcinoma | Hyperthermic Intraperitoneal Chemotherapy | Ruptured Liver
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation

Hepatocellular Carcinoma | Liver Transplant; Complications

Italy
Chang Gung Memorial Hospital

Not yet recruiting

Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clinical Trial

Hepatocellular Carcinoma
Zhujiang Hospital

Recruiting

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Hepatocellular Carcinoma Resectable

China
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
China Medical University Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis

Surgery | Hepatocellular Carcinoma Recurrent

Taiwan
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
University of Bologna
Azienda Ospedaliera Città della Salute e della Scienza di Torino; IRCCS Azienda... and other collaborators

Not yet recruiting

HOPE to Reduce Tumour Recurrence After LT In Patients With HCC (POTERE)

Liver Transplantation | Hepatocellular Carcinoma | Liver Cancer | Tumor Recurrence | Ex-vivo Hypothermic Perfusion

Italy
University Hospital, Ghent
Universitaire Ziekenhuizen KU Leuven; University Hospital, Antwerp; Cliniques...

Recruiting

Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma (GLITCA)

Liver Transplantation | Hepatocellular Carcinoma | Prognostic Biomarker | Diagnostic Biomarker

Belgium
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Beijing Hospital

Recruiting

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Kaoshiung Chang Gung Memorial Hospital

Recruiting

Lenvatinib Therapy in HCC Patients After LDLT

Liver Transplantation | Hepatocellular Carcinoma

Taiwan
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Anhui Provincial Hospital

Not yet recruiting

Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma

HCC
Seoul National University Hospital
RF medical

Recruiting

No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes

Chronic Liver Disease and Cirrhosis | Recurrent Hepatocellular Cancer

Korea, Republic of
Sun Yat-sen University

Recruiting

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

Hepatocellular Carcinoma | Liver Cancer | Recurrent Tumor | Microwave Ablation | Lenvatinib

China
Anhui Provincial Hospital
Henan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...

Recruiting

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
University Hospital, Rouen

Not yet recruiting

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA (REMNANT)

Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation

Hepatocellular Carcinoma Recurrent | Post-orthotopic Liver Transplantation

China
Newish Technology (Beijing) Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Fudan University

Recruiting

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma

China
Southwest Hospital, China

Recruiting

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) (RANT)

Hepatocellular Carcinoma Recurrent

China
University of Liege
Universitaire Ziekenhuizen KU Leuven; University Hospital, Ghent; University... and other collaborators

Recruiting

Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

Hepatocellular Carcinoma

Belgium
Chinese PLA General Hospital
Immunotech Applied Science Ltd.

Recruiting

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma (HCC)

China
National Cancer Centre, Singapore
Nanyang Technological University; Duke-NUS Graduate Medical School; MiRXES Pte... and other collaborators

Recruiting

Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma (PROSECT)

Hepatocellular Carcinoma

Singapore
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
Emory University
National Cancer Institute (NCI); Eisai Co., Ltd.

Recruiting

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditions

United States
Zhejiang University
Shandong Cancer Hospital and Institute; First Hospital of China Medical University and other collaborators

Recruiting

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma | Adjuvant Therapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

Hepatocellular Carcinoma | Lenvatinib

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
Ming Zhao

Recruiting

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

Recurrent Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
RenJi Hospital

Recruiting

Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence (HELP-2020)

Liver Transplant; Complications | Hepatocellular Carcinoma Recurrent

China
Centro Hospitalar de Lisboa Central
Ophiomics - Precision Medicine

Recruiting

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma (HepatoPredict)

Recurrence Tumor | Hepatocellular Carcinoma, Scirrhous

Portugal
Zhejiang University

Recruiting

Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients (CISLD-8)

Hepatocellular Carcinoma

China
Taipei Veterans General Hospital, Taiwan

Recruiting

Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence

HCC Patients After Curative Treatment With Low HBV Viral Load

Taiwan
University Health Network, Toronto
Ipsen

Recruiting

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Hepatocellular Carcinoma | Liver Transplant | Recurrent Cancer

Canada

Search clinical trials for: Hepatocellular Carcinoma Recurrence

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations